OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
DUBLIN, Ireland, Feb. 01, 2016 -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in two upcoming meetings:
- BIO CEO & Investor Conference on February 8, 2016 in New York, NY. Prothena President and Chief Executive Officer Dale B. Schenk, PhD will present an update on the company’s business at 10:00 AM ET and participate in a fireside chat at 1:30 PM ET.
- Leerink Partners 5th Annual Global Healthcare Conference on February 11, 2016 at 8:55 AM ET in New York, NY.
A live webcast of the presentations from both conferences can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, replays of the webcasts will be available on the Company's website for at least 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The company is developing antibody-based product candidates that target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and psoriasis and other inflammatory diseases (PRX003).
For more information, please visit the company's web site at www.prothena.com.
Contacts Investors: Tran Nguyen, CFO 650-837-8535, [email protected] Media: Ellen Rose 650-922-2405, [email protected]
